Treatment with glatiramer acetate can reduce by almost half the risk of patients progressing from the very early signs of multiple sclerosis (MS) to clinically definite disease, according to a study published early online and in an upcoming edition of The Lancet.
Giancarlo Comi, MD, Department of Neurology, University Vita-Salute, Milan, Italy, and colleagues conducted a randomised, double-blind trial at 80 sites in 16 countries.
A total of 481 patients presenting with a clinically isolated syndrome were randomly assigned to receive either subcutaneous glatiramer acetate 20 mg per day (n = 243) or placebo (n = 238) for up to 36 months, unless they converted to clinically definite MS.
................................................................................
Keep Informed and Up-to-Date with MS News and information:
If not yet registered to receive the " Stu's Views and MS Related News",weekly Multiple Sclerosis e-newsletter, then pleaseClick Hereto register.
...........................................................................
Giancarlo Comi, MD, Department of Neurology, University Vita-Salute, Milan, Italy, and colleagues conducted a randomised, double-blind trial at 80 sites in 16 countries.
A total of 481 patients presenting with a clinically isolated syndrome were randomly assigned to receive either subcutaneous glatiramer acetate 20 mg per day (n = 243) or placebo (n = 238) for up to 36 months, unless they converted to clinically definite MS.